# Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Source: https://onco.cc/trials/nct06937177/  
OnCo record `nct06937177` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TCMCB07 in colorectal cancer, run by Endevica Bio, now recruiting.

## Summary

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy is a phase 2 interventional study registered as NCT06937177 by Endevica Bio, with 120 participants planned, started 2025-04-28 and due to reach its primary completion in 2027-10. Interventions recorded: TCMCB07 and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06937177
- Phase: 2
- Setting: Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
- Sponsor: Endevica Bio
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06937177: https://clinicaltrials.gov/study/NCT06937177

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct06937177.json